Abstract: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.

Abstract: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl -methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.

Abstract: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said to capsule comprising said suspension formulation and to the packaging material for the finished capsule.

Abstract: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.

Abstract: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.

Abstract: Compositions in the form of solid solutions containinga) 1-90% by weight of a coumarin derivative A from the group of alkoxycoumarins with a heterocyclic substituent or of hydroxycoumarins esterified with a sulfonic acid as active substance andb) 10-99% by weight of at least one water-soluble polymer B as carrier substance.

Abstract: Compounds of the formula ##STR1## where A-B-D, R.sup.1, R.sup.2 and R.sup.3 have the meanings stated in the description, and their preparation are described. The compounds are suitable for controlling diseases.

Abstract: The present invention relates to a process for the preparation of finished dyeings of high fastness to thermomigration on fibre materials consisting completely or partly of polyester, characterized in that the material is dyed with one or more dyestuffs of the general formula I ##STR1## wherein R denotes linear (C.sub.1 -C.sub.3)-alkyl or (C.sub.3 -C.sub.6)-alkyl which is interrupted by an oxygen atom andR.sup.1 denotes (C.sub.1 -C.sub.4)-alkyl,and the dyeing thus obtained is then finished.

Abstract: Phenylpiperidylamines of the formula I ##STR1## R.sup.1 is H, NO.sub.2, R.sup.4 SO.sub.2 NH, ##STR2## N.dbd.C, CF.sub.3, CF.sub.3 O, F, Cl, Br, C.sub.1 -C.sub.4 -alkyl, R.sup.3 O, CO.sub.2 R.sup.3, CHO, CH.dbd.NOR.sup.3, CH.sub.3 OR.sup.3 andR.sup.2 is H, F, Cl, Br, C.sub.1 -C.sub.4 -alkyl or R.sup.4 O, where R.sup.1 and R.sup.2 are not both H,R.sup.3 is H or R.sup.4,R.sup.4 is C.sub.1 -C.sub.4 -alkyl or phenyl,n is 1, 2, 3 or 4 andAr is ##STR3## and the physiologically tolerated salts thereof, are used as active ingredients in drugs.

Abstract: Coupling products of diazotized o- or p-toluidines to 3-hydroxy-2-naphthoic acid p-anisidide do not produce optimum dyeing properties in HT exhaustion dyeing of wound packages of synthetic fiber materials. Filtration occurs time after time under critical conditions, since these single dyestuffs and also mixtures of these with one another build up too slowly in the heating-up phase.A bright red multi-component system of the same color shade, which exhibits a significantly improved exhaustion capacity by synergism during HT dyeing of wound packages and no longer presents difficulties in respect of filtration, can be obtained by mixing monoazo dyestuffs which are obtained by coupling diazotized aniline and p-toluidine in each case to 3-hydroxy-2-naphthoic acid p-anisidide.

Abstract: Phenylpiperidinylamines of the formula I ##STR1## where R.sup.1 is --NHSO.sub.2 R.sup.4 or ##STR2## R.sup.2 and R.sup.3 are each, independently of one another, H or C.sub.1 -C.sub.4 -alkyl or together are a (CH.sub.2).sub.n chain with n=4 or 5, andR.sup.4 is C.sub.1 -C.sub.4 -alkyl or phenyl,and the physiologically tolerated salts thereof, and pharmaceutical compositions containing these are described.

Abstract: The present invention relates to the .beta.-modification of the dye of the formula I ##STR1## to a process for its preparation, to its use, and to a dye preparation containing it.

Abstract: Compounds of the formula ##STR1## where R.sup.1, R.sup.2, R.sup.3 and A have the meanings stated in the specification, as well as the use thereof for controlling diseases, are described.

Abstract: Compounds of the formula ##STR1## where R.sup.1, R.sup.2, R.sup.3, R.sup.4 and A have the meanings stated in the specification, as well as the use thereof for controlling diseases, are described.

Abstract: A sun visor provided with a protective sun visor plate for the windshield of a vehicle whose protective sun visor plate is pivotally and axially displaceably supported on a horizontal mounting rod whereby the mounting rod is pivotally retained in a fixed bearing support about an approximately vertical axis by way of an angularly bent area; in order to obviate a separate displacement of the sun visor into its optimum axial position, when pivoting the sun visor in front of the window of the coordinated side door, provision is made according to the present invention that a lever which, on the one hand, is operatively connected with the protective sun visor plate and, on the other hand, is pivotally secured at the vehicle, is so arranged that during the pivoting of the mounting rod about the approximately vertical axis, an axial displacement of the protective sun visor plate on the mounting rod is automatically effected.